Waters Co. (NYSE:WAT) Expected to Announce Earnings of $2.11 Per Share

Analysts forecast that Waters Co. (NYSE:WAT) will post $2.11 earnings per share for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Waters’ earnings, with the lowest EPS estimate coming in at $2.09 and the highest estimate coming in at $2.14. Waters posted earnings per share of $1.95 during the same quarter last year, which indicates a positive year over year growth rate of 8.2%. The firm is expected to report its next earnings results on Tuesday, July 23rd.

According to Zacks, analysts expect that Waters will report full-year earnings of $9.11 per share for the current year, with EPS estimates ranging from $9.07 to $9.17. For the next fiscal year, analysts forecast that the firm will post earnings of $10.26 per share, with EPS estimates ranging from $9.72 to $10.99. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Waters.

Waters (NYSE:WAT) last announced its quarterly earnings data on Tuesday, April 23rd. The medical instruments supplier reported $1.60 earnings per share for the quarter, missing the consensus estimate of $1.73 by ($0.13). Waters had a net margin of 24.59% and a return on equity of 39.64%. The company had revenue of $513.90 million for the quarter, compared to analyst estimates of $545.82 million. During the same quarter in the prior year, the company posted $1.59 EPS. Waters’s revenue for the quarter was down 3.2% on a year-over-year basis.

WAT has been the subject of several recent research reports. Zacks Investment Research downgraded shares of Waters from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 12th. Cleveland Research downgraded shares of Waters from a “neutral” rating to an “underperform” rating in a research report on Wednesday, June 12th. UBS Group decreased their target price on shares of Waters from $248.00 to $230.00 and set a “neutral” rating for the company in a research report on Wednesday, April 24th. Barclays decreased their target price on shares of Waters from $218.00 to $210.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 24th. Finally, ValuEngine downgraded shares of Waters from a “buy” rating to a “hold” rating in a research report on Wednesday, April 24th. Four analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $208.71.

Shares of NYSE WAT opened at $215.24 on Friday. The firm’s 50-day moving average is $207.91. Waters has a 1-year low of $167.93 and a 1-year high of $255.21. The firm has a market capitalization of $14.66 billion, a price-to-earnings ratio of 25.96, a P/E/G ratio of 2.23 and a beta of 1.08. The company has a quick ratio of 2.89, a current ratio of 3.44 and a debt-to-equity ratio of 1.15.

Several large investors have recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. grew its stake in Waters by 4.2% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 1,792 shares of the medical instruments supplier’s stock valued at $338,000 after purchasing an additional 72 shares in the last quarter. Canada Pension Plan Investment Board grew its position in shares of Waters by 23.8% in the 4th quarter. Canada Pension Plan Investment Board now owns 21,811 shares of the medical instruments supplier’s stock worth $4,114,000 after acquiring an additional 4,200 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Waters by 40.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 11,213 shares of the medical instruments supplier’s stock worth $2,116,000 after acquiring an additional 3,211 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its position in shares of Waters by 4.1% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 42,819 shares of the medical instruments supplier’s stock worth $8,048,000 after acquiring an additional 1,680 shares in the last quarter. Finally, Tredje AP fonden grew its position in shares of Waters by 103.2% in the 4th quarter. Tredje AP fonden now owns 4,443 shares of the medical instruments supplier’s stock worth $838,000 after acquiring an additional 2,257 shares in the last quarter. 92.57% of the stock is owned by institutional investors.

About Waters

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Featured Article: Asset Allocation and Your Retirement

Get a free copy of the Zacks research report on Waters (WAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.